Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ARID1A deficiency associated with MMR deficiency and a high abundance of tumor-infiltrating lymphocytes predicts a good prognosis of endometrial carcinoma

1 May 2023

Abstract excerpt

• ARID1A alterations are common in EC patients, and their presence is related to a good prognosis as an independent prognostic factor. • ARID1A alterations were found to co-occur with mutations in MMR-related genes, and patients concomitantly harboring alterations of ARID1A and MMR-related gene mutations achieved the best prognosis. • ARID1A expression loss is also an independent prognostic factor and is related...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Ferroptosis and cancer prognosis
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37137217
DOI: 10.1016/j.tranon.2023.101685

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ARID1A deficiency associated with MMR deficiency and a high abundance of tumor-infiltrating lymphocytes predicts a good prognosis of endometrial carcinomaPMID 37137217Read ↗

The features and prognostic value of ARID1A mutation and protein expression in endometrial cancer of no specific molecular profile (NSMP) subtype: a retrospective study in a large Chinese cohort.Semantic proximity Read ↗

Evaluation of ARID1A as a Potential Biomarker for Predicting Response to Immune Checkpoint Inhibitors in Patients with Endometrial CancerSemantic proximity Read ↗

ARID1A in Gynecologic Precancers and Cancers.Semantic proximity Read ↗

The roles of ARID1A in gynecologic cancerSemantic proximity Read ↗

ARID1A is a useful marker of malignancy in peritoneal washings for endometrial carcinoma.Semantic proximity Read ↗

Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian CarcinomaSemantic proximity Read ↗

Prognostic role of transcription factor ARID1A in patients with endometrial cancer of no specific molecular profile (NSMP) subtype.Semantic proximity Read ↗

Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.Semantic proximity Read ↗

Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinomaSemantic proximity Read ↗

Landscape of chromatin remodeling gene alterations in endometrial carcinoma.Semantic proximity Read ↗

Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancersSemantic proximity Read ↗

ARID1A: gene, protein, and function in endometrial cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.